Despite near universal availability of nirsevimab, only 35% of eligible children receive nirsevimab for RSV prophylaxis.

Despite adequate availability of nirsevimab, only about one third of eligible children receive it for respiratory syncytial virus prophylaxis, with uptake varying by race and other social factors.

Despite strong clinical data, RSV immunization rates among pregnant women and older adults remain worryingly low, ...

Vulnerable premature babies needing extra protection against RSV will receive a long-lasting single injection of nirsevimab, ...

A large-scale real-world study in the USA has reinforced the effectiveness of Beyfortus (nirsevimab-alip), the respiratory ...

Today, the Federation of Medical Women of Canada (FMWC) released its latest white paper through the Maternal RSV Task Force—a ...

Dr Reddy's Laboratories reported a 1.4% increase in consolidated net profit to ₹1,409 crore for Q1FY26, compared to ₹1,392 ...

MORRISTOWN, NJ, USA I July 22, 2025 I The largest US real-world study of BEYFORTUS (nirsevimab-alip) 50mg and 100mg Injection successfully met both of its ...

A new respiratory syncytial virus vaccine to protect infants from severe illness is available in South Africa’s private ...

Babies born very prematurely will be offered protection against respiratory syncytial virus (RSV) with a long-acting antibody ...

Thousands of at-risk infants – including those born prematurely in Andover and across Hampshire – will receive long-lasting protection against RSV through a new NHS immunisation programme.